title: "Adherent" versus Other Isolation Strategies for Expanding Purified, Potent, and Activated Human NK Cells for Cancer Immunotherapy.
abstract: Natural killer (NK) cells have long been hypothesized to play a central role in the development of new immunotherapies to combat a variety of cancers due to their intrinsic ability to lyse tumor cells. For the past several decades, various isolation and expansion methods have been developed to harness the full antitumor potential of NK cells. These protocols have varied greatly between laboratories and several have been optimized for large-scale clinical use despite associated complexity and high cost. Here, we present a simple method of "adherent" enrichment and expansion of NK cells, developed using both healthy donors' and cancer patients' peripheral blood mononuclear cells (PBMCs), and compare its effectiveness with various published protocols to highlight the pros and cons of their use in adoptive cell therapy. By building upon the concepts and data presented, future research can be adapted to provide simple, cost-effective, reproducible, and translatable procedures for personalized treatment with NK cells.
authors.affiliation: Division of Solid Tumor, Department of Medical Oncology, Thomas Jefferson University, Curtis Building, Suite 1024B, 1015 Walnut Street, Philadelphia, PA 19107, USA.
authors.forename: Senthamil R
authors.initials: SR
authors.lastname: Selvan
authors.affiliation: Immunology and Microbial Pathogenesis Graduate Program, Thomas Jefferson University, Philadelphia, PA 19107, USA.
authors.forename: John P
authors.initials: JP
authors.lastname: Dowling
mesh_terms: D064987:Cell- and Tissue-Based Therapy; D006801:Humans; D007167:Immunotherapy; D007694:Killer Cells, Natural / Q000166:cytology / Q000276:immunology*; D007963:Leukocytes, Mononuclear / Q000276:immunology*; D009369:Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D057285:Precision Medicine